Other languages Newbury Pharmaceuticals AB

Equities

NEWBRY

SE0015244884

Delayed Nasdaq Stockholm Other stock markets 04:56:18 2024-07-11 am EDT			5-day change	1st Jan Change
3.22 ^SEK	-1.23%		-2.42%	+4.89%

Jul. 10	Newbury Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024	CI
Jun. 20	Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Newbury Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024	Jul. 10
Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen	Jun. 20
Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 10
Newbury Pharmaceuticals Secures SEK9 Million Sales Order	Feb. 22
Newbury Pharmaceuticals Receives International Sales Order Valued At 8.8 Million	Feb. 22
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 10
Newbury Pharmaceuticals AB Reports Earnings Results for the Full Year Ended August 31, 2023	23-10-11
Newbury Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended August 31, 2023	23-10-11
Newbury, Amarox Sign Distribution Deal for Sweden, Denmark	23-10-06
Newbury Signs Contract with Amarox Limited to Represent and Distribute Their Products in Sweden and Denmark	23-10-06
Newbury Pharmaceuticals Strengthens its Portfolio with Levodopa/Benserazide	23-09-22
Newbury Secures Access to Hospital Product Portfolio in New Partnership	23-08-23
Newbury Pharmaceuticals AB Gains Access to the Nordic Hospital Market with A New Strategic Partnership for Prescription Medicine	23-08-23
Newbury Pharmaceuticals Gets OK to Sell Peptide Product in Sweden	23-07-19
Newbury Pharmaceuticals Announces the Marketing Authorization of Desmopressin Newbury 60, 120 & 240 Mg Sublingual Tablets in Sweden	23-07-19
Newbury Pharmaceuticals AB Provides Earnings Guidance for the Year 2028	23-06-16
Newbury Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-06-14
Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-12
Newbury Pharmaceuticals Announces the Marketing Authorization of Lapatinib Newbury 250 Mg Film-Coated Tablets in Sweden	23-03-24
Newbury Pharmaceuticals' MS Treatment Receives Marketing Authorization in Sweden	23-03-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Newbury Pharmaceuticals AB

Equities

NEWBRY

SE0015244884

Other languages

Filters